Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
1. A method of diagnosing cutaneous T-cell lymphoma (CTCL) in a subject, comprising:
(a) obtaining a biological sample from a subject;
(b) contacting the biological sample with means for determining expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3;
(c) determining levels of expression of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 in the biological sample of the subject relative to expression levels in a biological sample of a subject who does not suffer from CTCL,
(d) providing a diagnosis of CTCL, wherein the determined expression level of TOX is more than 5 fold; the determined expression level of PLS3 is more than 10 fold; the determined expression level of KIR3DL2 is more than 5 fold; the determined expression level of GATA3 is more than about 1.75 fold; and the determined expression level of RUNX3 is less than about 60%; all relative to the expression levels of a subject who does not suffer from cutaneous T-cell lymphoma.
2. The method of claim 1 , where expression is determined using quantitative real-time polymerase chain reaction or antibody-mediated detection methods.
3. The method of claim 1 , where expression is determined by a method comprising one or more of determining levels of RNA, array analysis, Northern blot analysis, determining levels of protein expression, antibody-binding, probe hybridization, real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), real time PCR, immunohistochemistry, and/or Western blot.
4. The method of claim 1 , wherein the expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 are determined by a polymerase chain reaction (PCR) and/or a real-time PCR.
5. The method of claim 1 , wherein the expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 are determined by a quantitative real-time PCR and/or a quantitative reverse transcription PCR.
6. The method of claim 1 , wherein the expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 are determined by immunohistochemistry.
7. The method of claim 1 , wherein the biological sample obtained from the subject is a blood sample.
8. The method of claim 1 , wherein the biological sample obtained from the subject comprises peripheral blood mononuclear cells obtained from the subject.
9. The method of claim 1 , wherein the sample obtained from the subject comprises peripheral blood CD4+ T-cells.
10. The method of claim 1 , wherein the subject has a skin lesion.
11. The method of claim 1 , wherein the sample obtained from the subject comprises cells of the skin lesion.